Cargando…

Psychiatric morbidity among men using anabolic steroids

OBJECTIVE: The purpose of this study was to investigate the psychiatric morbidity among men with abuse of anabolic steroids. METHODS: The design is a retrospectively matched cohort study. Five hundred and fourty‐five males, who tested positive for anabolic steroids in Danish fitness centers during t...

Descripción completa

Detalles Bibliográficos
Autores principales: Windfeld‐Mathiasen, Josefine, Christoffersen, Thea, Strand, Niels August Willer, Dalhoff, Kim, Andersen, Jon Trærup, Horwitz, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092709/
https://www.ncbi.nlm.nih.gov/pubmed/36281632
http://dx.doi.org/10.1002/da.23287
_version_ 1785023412155973632
author Windfeld‐Mathiasen, Josefine
Christoffersen, Thea
Strand, Niels August Willer
Dalhoff, Kim
Andersen, Jon Trærup
Horwitz, Henrik
author_facet Windfeld‐Mathiasen, Josefine
Christoffersen, Thea
Strand, Niels August Willer
Dalhoff, Kim
Andersen, Jon Trærup
Horwitz, Henrik
author_sort Windfeld‐Mathiasen, Josefine
collection PubMed
description OBJECTIVE: The purpose of this study was to investigate the psychiatric morbidity among men with abuse of anabolic steroids. METHODS: The design is a retrospectively matched cohort study. Five hundred and fourty‐five males, who tested positive for anabolic steroids in Danish fitness centers during the period January 3, 2006 to March 1, 2018, were matched with 5450 randomly chosen male controls. Data was cross‐referenced with seven national registers pertaining to information about education, employment status, and psychiatric comorbidity. Main outcomes and measures were prescription of psychopharmacological treatment. RESULTS: The incidence of treatment with anxiolytics (HR: 2.34, 95% CI: 1.62−3.38) and antipsychotics (HR: 2.69, 95% CI: 1.99−3.63) displayed a remarkable increase in the years following doping sanction, compared to the control group. The prevalence of antidepressant use was already markedly elevated several years before doping sanction, but also displayed a higher incidence in the years following sanction (HR: 1.65, 95% CI: 1.28−2.13). The associations remained highly significant after controlling for socioeconomic factors. CONCLUSION: Anabolic steroids use is strongly associated with psychiatric morbidity.
format Online
Article
Text
id pubmed-10092709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100927092023-04-13 Psychiatric morbidity among men using anabolic steroids Windfeld‐Mathiasen, Josefine Christoffersen, Thea Strand, Niels August Willer Dalhoff, Kim Andersen, Jon Trærup Horwitz, Henrik Depress Anxiety Research Report OBJECTIVE: The purpose of this study was to investigate the psychiatric morbidity among men with abuse of anabolic steroids. METHODS: The design is a retrospectively matched cohort study. Five hundred and fourty‐five males, who tested positive for anabolic steroids in Danish fitness centers during the period January 3, 2006 to March 1, 2018, were matched with 5450 randomly chosen male controls. Data was cross‐referenced with seven national registers pertaining to information about education, employment status, and psychiatric comorbidity. Main outcomes and measures were prescription of psychopharmacological treatment. RESULTS: The incidence of treatment with anxiolytics (HR: 2.34, 95% CI: 1.62−3.38) and antipsychotics (HR: 2.69, 95% CI: 1.99−3.63) displayed a remarkable increase in the years following doping sanction, compared to the control group. The prevalence of antidepressant use was already markedly elevated several years before doping sanction, but also displayed a higher incidence in the years following sanction (HR: 1.65, 95% CI: 1.28−2.13). The associations remained highly significant after controlling for socioeconomic factors. CONCLUSION: Anabolic steroids use is strongly associated with psychiatric morbidity. John Wiley and Sons Inc. 2022-10-25 2022-12 /pmc/articles/PMC10092709/ /pubmed/36281632 http://dx.doi.org/10.1002/da.23287 Text en © 2022 The Authors. Depression and Anxiety published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Report
Windfeld‐Mathiasen, Josefine
Christoffersen, Thea
Strand, Niels August Willer
Dalhoff, Kim
Andersen, Jon Trærup
Horwitz, Henrik
Psychiatric morbidity among men using anabolic steroids
title Psychiatric morbidity among men using anabolic steroids
title_full Psychiatric morbidity among men using anabolic steroids
title_fullStr Psychiatric morbidity among men using anabolic steroids
title_full_unstemmed Psychiatric morbidity among men using anabolic steroids
title_short Psychiatric morbidity among men using anabolic steroids
title_sort psychiatric morbidity among men using anabolic steroids
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092709/
https://www.ncbi.nlm.nih.gov/pubmed/36281632
http://dx.doi.org/10.1002/da.23287
work_keys_str_mv AT windfeldmathiasenjosefine psychiatricmorbidityamongmenusinganabolicsteroids
AT christoffersenthea psychiatricmorbidityamongmenusinganabolicsteroids
AT strandnielsaugustwiller psychiatricmorbidityamongmenusinganabolicsteroids
AT dalhoffkim psychiatricmorbidityamongmenusinganabolicsteroids
AT andersenjontrærup psychiatricmorbidityamongmenusinganabolicsteroids
AT horwitzhenrik psychiatricmorbidityamongmenusinganabolicsteroids